Also, several studies showed a significant impact of the TP53 mutations on OS of DLBCL patients [22, 34, 35] and that was similar to our results that showed worse 2-year PFS and OS rates regarding mutant TP53 with a significant P value less than 0.001. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.